Citations

Clear

3138 citation(s) found for "Smith, AM".

Effect of Reproductive History on Kidney Structure and Function in Women
Kattah, Andrea G. , Mullan, Aidan F. , Garovic, Vesna D. , Smith, Maxwell L. , Đenić, Aleksandar , Stegall, Mark D. , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 685-685

10.1681/asn.20213210s1685b Get It

Characterization of Porcine Models of Autosomal Recessive Polycystic Kidney Disease
Smith, Jessica M. , Coutts, Alexander , Wells, Harrison H. , Coutts, Alexander W., Tschida, Barbara R , Carlson, Daniel F. , Harris, Peter C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 485-486

10.1681/asn.20203110s1485e Get It

Abstract 10: Trends in Blood Pressure Control With the Covid-19 Pandemic, 2017 to 2022: A Study of 17 US Health Systems in the PCORnet ® Blood Pressure Control Laboratory
Shaw, Kathryn M., Smith, Myra, O’Brien, Emily C. , Chamberlain, Alanna M. , Cooper‐DeHoff, Rhonda M. , Lin, Feng , Fontil, Valy , Carton, Thomas W. , Modrow, Madelaine Faulkner , Wozniak, Gregory , Rakotz, Michael , Smith, Steven M. , Pletcher, Mark J.

Mayo Clinic

Circulation | May 16, 2024 | Volume: 149 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.149.suppl_1.10 Get It

Background: The COVID-19 pandemic resulted in reduced in-person clinic visits and declines in blood pressure (BP) control among patients with hypertension. The purpose of this study was to report on pre- to post-pandemic trends in BP control and related BP metrics through 2022. Methods: We utilized data from 17 US health systems with electronic health record data standardized to the PCORnet ® Common Data Model. Multiple BP control metrics were calculated as a series of quarterly, 12-month rolling measurement periods from 2017 to 2022 (i.e., 1/1/2017-12/31/2017, 4/1/2017-3/31/2018, …, 1/1/2022-12/31/2022). BP control was defined as the percentage of patients with hypertension whose most recent BP measurement at an ambulatory visit was <140/<90 mmHg. Improvement in BP was defined as the percentage of patients with a reduction of 10 mmHg in systolic BP or achievement of systolic BP <140 mmHg during the last 3 months of the measurement period in patients with previously uncontrolled hypertension. Results: In 2022, 1,499,418 persons with hypertension were included (50% 65-85 years old; 47% men; 11% Hispanic, 3% non-Hispanic Asian, 20% non-Hispanic Black, 63% non-Hispanic White). BP control was relatively stable within health systems prior to the COVID-19 pandemic. Worsening of BP control was seen for most health systems in the second quarter of 2020 coinciding with onset of the COVID-19 pandemic (Figure, left panel). The weighted average BP control was 65.3% in 2019, dropped to 61.8% in 2020, and increased to 62.9% in 2021 and 62.6% in 2022. Similar patterns were observed for the improvement in BP metric (Figure, right panel): weighted average 31.4% in 2019, 25.7% in 2020, 29.1% in 2021 and 28.6% in 2022. Conclusion: BP control and improvement in BP decreased substantially during the COVID-19 pandemic. While both metrics improved after 2020, they were still below pre-pandemic levels through 2022. These findings underscore the importance of continued surveillance of BP control and other health impacts of the COVID-19 pandemic.
Defining the “ideal state”: A primer on critical care pharmacy practice models
Smith, Susan , Nei, Andrea M.

Mayo Clinic

American Journal of Health-System Pharmacy | May 14, 2024 | Volume: 81 | Issue: 18 | Pages: 796-811

10.1093/ajhp/zxae135 | PMID 38741290 Get It

Abstract Purpose Critical care pharmacists (CCPs) have been clearly established as value-added members of the interprofessional team, and their contributions positively impact patient outcomes in the intensive care unit (ICU). Despite this, not every critically ill patient in the US receives care from a CCP and the model through which CCPs practice is variable, which has important implications. The purpose of this primer is to review current CCP models and discuss elements of the optimal CCP practice model. Summary Current CCP practice models are defined, including the drug processing and dispensing model, clinical pharmacy specialist model, integrated pharmacy generalist model, and hybrid model, as well as unit-based vs service-based models. The optimal CCP practice model considers the Triple Domain of CCP workload, which includes direct patient care, indirect patient care, and professional service. Elements of the ideal CCP practice model including 24/7/365 CCP services, unit- vs service-based models, prescriptive authority, operational support, and CCP-to-patient ratio are discussed. Other vital elements include dedicated offline time, use of appropriate workload metrics, development of career ladders, opportunities for professional development, and providing wellness resources. The ideal CCP practice model must also be considered through the lens of the patient and medical team, the CCP, the institution, and professional organizations. Strategies for optimizing current CCP practice models are provided, and application of optimal CCP practice model elements is explored through 5 case studies. Conclusion The optimal CCP practice model includes multiple elements and incorporates the viewpoints of patients, providers, CCPs, institutions, and professional organizations; this model will increase access of all ICU patients to CCPs, enhance the scope of CCP cognitive services, and ensure the economic sustainability of CCP practice while establishing CCP involvement in activities outside of patient care and in professional service.
Analgesia for the treatment of acute pancreatitis: a protocol for a systematic review and network meta-analysis
Subramani, Sriya S, Berg, Alaina , Král, L , Murad, M. Hassan , Smith, Abigail , Phillips, Anna Evans , Yadav, Dhiraj , Uç, Aliye , Berg, Alaina C , Murad, M Hassan , Imdad, Aamer

Mayo Clinic

BMJ Open | May 13, 2024 | Volume: 14 | Issue: 5 | Pages: e081971

10.1136/bmjopen-2023-081971 | PMID 38740508 Get It

Introduction Gastrointestinal hospitalisations in the USA cause over US$130 billion in expenditures, and acute pancreatitis is a leading cause of these hospitalisations. Adequate pain control is one of the primary treatment goals for acute pancreatitis. Though opioids are commonly used for analgesia in these patients, there have been concerns about short-term and long-term side effects of using opioids. Recently, non-opioid medications have been studied to treat pain in patients with acute pancreatitis. This systematic review and network meta-analysis aims to assess the comparative efficacy of analgesic medication for non-severe, acute pancreatitis. Methods and analysis We will search multiple electronic databases for randomised controlled trials that study pain management in patients with non-severe, acute pancreatitis. The intervention will be any analgesic for acute pancreatitis in the hospital setting. The comparison group will be patients who received a placebo or other active interventions for pain management. The primary outcomes of interest include pain scores and the need for supplementary analgesia. The secondary outcomes will be serious adverse events, local complications, progression to severe pancreatitis, transfer to the intensive care unit, length of hospitalisation, time to start enteral feeds, 30-day all-cause mortality and Quality of Life Scale scores. If sufficient homogeneity exists among included studies, the findings will be pooled using a traditional pairwise and network meta-analysis. The risk of bias in randomised control trials will be evaluated using the Cochrane Risk of Bias Tool 2.0. The Grading of Recommendations, Assessment, Development, and Evaluation approach will be used to report the certainty of evidence. Ethics and dissemination This systematic review will not involve direct contact with human subjects. The findings of this review will be published in a peer-reviewed journal. They will give healthcare providers a better awareness of the optimal analgesic medication for pain treatment in non-severe, acute pancreatitis.
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
Bhansali, Rahul S. , Ellin, Fredrik , Relander, Thomas, Cao, Miao , Li, Wenrui , Long, Qi , Ganesan, Nivetha , Stuver, Robert , Wudhikarn, Kitsada, Sokol, Lubomir, Duan, Frank, Pullarkat, Priyanka, Mehta–Shah, Neha , Ruiz, Miguel , Brammer, Jonathan E. , Prakash, Rishab, Iyer, Swaminathan P. , Major, Ajay , Smith, Sonali M. , Goldin, Caroline, Haverkos, Bradley M. , Zhuang, Tony , Allen, Pamela B. , Toama, Wael , Janakiram, Murali , Brooks, Taylor , Jagadeesh, Deepa, Hariharan, Nisha , Goodman, Aaron M. , Hartman, Gabrielle, Fayyaz, Fatima , Gerson, James N. , Svoboda, Jakub , Long, Qi , Wudhikarn, Kitsada , Hwang, Steven R , Bennani, N Nora , Saeed, Hayder , Porcu, Pierluigi , Mehta-Shah, Neha , Zain, Jasmine , Olszewski, Adam J , Smith, Sonali M , Haverkos, Bradley M , Hu, Bei , Zhuang, Tony Z , Allen, Pamela Blair , Toama, Wael , Brooks, Taylor R , Ghione, Paola , Fayyaz, Fatima , Rhodes, Joanna , Chong, Elise A , Barta, Stefan K , Major, Ajay , Janakiram, Murali , Bhansali, Rahul S , Stuver, Robert , Horwitz, Steven M. , Hwang, Steven R. , Bennani, N. Nora , Chavez, Julio C , Olszewski, Adam J. , Riedell, Peter A. , Hu, Bei , Jagadeesh, Deepa , Hariharan, Nisha, Ghione, Paola , Rhodes, Joanna , Chong, Elise A. , Landsburg, Daniel J. , Nasta, Sunita , Schuster, Stephen J. , Jerkeman, Mats

Mayo Clinic

Blood Advances | May 13, 2024 | Volume: 8 | Issue: 13 | Pages: 3507-3518

10.1182/bloodadvances.2024012800 | PMID 38739715 Get It

Abstract Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS relapse in patients with MTNKN and developed the CNS relapse In T-cell lymphoma Index (CITI) to predict patients at the highest risk of CNS relapse. We reviewed data from 135 patients with MTNKN and CNS relapse from 19 North American institutions. After exclusion of leukemic and most cutaneous forms of MTNKNs, patients were pooled with non-CNS relapse control patients from a single institution to create a CNS relapse–enriched training set. Using a complete case analysis (n = 182), including 91 with CNS relapse, we applied a least absolute shrinkage and selection operator Cox regression model to select weighted clinicopathologic variables for the CITI score, which we validated in an external cohort from the Swedish Lymphoma Registry (n = 566). CNS relapse was most frequently observed in patients with peripheral T-cell lymphoma, not otherwise specified (25%). Median time to CNS relapse and median overall survival after CNS relapse were 8.0 and 4.7 months, respectively. We calculated unique CITI risk scores for individual training set patients and stratified them into risk terciles. Validation set patients with low-risk (n = 158) and high-risk (n = 188) CITI scores had a 10-year cumulative risk of CNS relapse of 2.2% and 13.4%, respectively (hazard ratio, 5.24; 95% confidence interval, 1.50-18.26; P = .018). We developed an open-access web-based CITI calculator (https://redcap.link/citicalc) to provide an easy tool for clinical practice. The CITI score is a validated model to predict patients with MTNKN at the highest risk of developing CNS relapse.
Utilizing median and maximum QTc values improves prediction of breakthrough cardiac events in pediatric long QT syndrome
Rohatgi, Ram K., Tseng, Andrew S. , Sugrue, Alan , Lee, Alexander T. , Wackel, Phillip L., Cannon, Bryan C. , Bos, J. Martijn , Ackerman, Michael J. , Sugrue, Alan , Wackel, Philip , Ackerman, Michael J , Tseng, A S , Bos, Johan M , Scott, Christopher G.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 10, 2024 | Volume: 35 | Issue: 7 | Pages: 1370-1381

10.1111/jce.16293 | PMID 38725227 Get It

AbstractIntroductionAlthough prior studies indicate that a QTc > 500 ms on a single baseline 12‐lead electrocardiogram (ECG) is associated with significantly increased risk of arrhythmic events in long QT syndrome (LQTS), less is known about the risk of persistent QT prolongation. We sought to determine QTc persistence and its prognostic effect on breakthrough cardiac events (BCEs) among pediatric patients treated for LQTS.MethodsWe performed a retrospective analysis of 433 patients with LQTS evaluated, risk‐stratified, and undergoing active guideline‐based LQTS treatment between 1999 and 2019. BCEs were defined as arrhythmogenic syncope/seizure, sudden cardiac arrest (SCA), appropriate VF‐terminating ICD shock, and sudden cardiac death (SCD).ResultsDuring the median follow‐up of 5.5 years (interquartile range [IQR] = 3–9), 32 (7%) patients experienced a total of 129 BCEs. A maximum QTc threshold of 520 ms and median QTc threshold of 490 ms were determined to be strong predictors for BCEs. A landmark analysis controlling for age, sex, genotype, and symptomatic status demonstrated models utilizing both the median QTc and maximum QTc demonstrated the highest discriminatory value (c‐statistic = 0.93–0.95). Patients in the high‐risk group (median QTc > 490 ms and maximum QTc > 520 ms) had a significantly lower BCE free survival (70%–81%) when compared to patients in both medium‐risk (93%–97%) and low‐risk (98%–99%) groups.ConclusionsThe risk of BCE among patients treated for LQTS increases not only based upon their maximum QTc, but also their median QTc (persistence of QTc prolongation). Patients with a maximum QTc > 520 ms and median QTc > 490 ms over serial 12‐lead ECGs are at the highest risk of BCE while on guideline‐directed medical therapy.
Long-term Effects of COVID-19 on Vascular Parameters—A Prospective Longitudinal Ultrasound Clinical Study
Chen, James , Smith, Kane , Xu, Qian , Ali, T’shura , Cavallazzi, Rodrigo , Clifford, Sean P., Arnold, Forest W. , Huang, Jiapeng , Smith, Kane, Ghafghazi, Shahab , Kong, Maiying , Huang, Jiapeng

Mayo Clinic

Journal for Vascular Ultrasound | May 10, 2024 | Volume: 48 | Issue: 2 | Pages: 95-102

10.1177/15443167231210357 | PMID 39641110 Get It

Objective: To investigate the longitudinal effects of COVID-19 on major vascular structures and parameters and clinical outcomes. Design: Observational prospective trial. Setting: Post-COVID-19 research clinic established by University of Louisville Division of Infectious Diseases. Participants: The study population consisted of 72 post-COVID-19 individuals and 11 non-COVID-19 infected participants in the control group. The participants were recruited from adult hospitals and from the community. The enrollment started in October 2020 and follow-up periods were at 3, 6, and 12 months from their initial COVID-19 diagnosis. Interventions: The participants were interviewed for medical and COVID-19 infection history. Samples of white blood cell (WBC), C-reactive protein (CRP), and D-dimer were taken at each visit. Certified sonographers performed vascular ultrasound on the study participants. Measurements and Main Results: Median intima-media thickness (IMT) was increased in mild/asymptomatic (0.80 mm) and severe/critical (0.90 mm) groups when compared with controls (0.60 mm; P < .001 for both groups). In the asymptomatic/mild group, 6-month median IMT (0.88 mm) was increased, compared with the 3-month group (0.75 mm), with P = .026. Increased age was associated with decreased mean arterial blood velocities (cm/s): common carotid ( r = −0.236, P = .032), internal carotid ( r = −0.208, P = .048), and subclavian artery mean velocity ( r = −0.357, P = .003). We did not find any instance of deep vein thrombosis. Median D-dimer, CRP, and WBC in the control group differed from asymptomatic/mild COVID-19 group ( P = .026, .011, and .003, respectively). Moreover, WBC in the asymptomatic/mild group and moderate COVID-19 group differed from severe/critical group ( P = .025 and P = .027, respectively); CRP also differed between asymptomatic/mild group and severe/critical group ( P = .014). Conclusions: There were differences in intima-media lumen thickness (IMT), arterial velocities, and inflammatory markers in post-COVID-19 patients. There was no instance of deep vein thrombosis in this post-COVID-19 study cohort. The increased IMT might infer atherosclerosis, which has shown to increase cardiovascular risks. It is not yet known whether the increase in IMT due to COVID should be treated in the same way as non-COVID-19 atherosclerosis—through statins, for example—or whether regular cardiovascular risk reduction would be useful. Clinical trial and mechanistic studies should be performed to further our understanding of COVID-19-related vascular pathologies.
Genetic testing in early-onset atrial fibrillation
Kany, Shinwan , Jurgens, Sean J. , Rämö, Joel , Rienstra, Michiel , Chung, Mina K. , Ackerman, Michael J. , McNally, Elizabeth M. , Semsarian, Christopher , Wilde, Arthur A.M., Roden, Dan M. , Shoemaker, M. Benjamin , Rienstra, Michiel , Ackerman, Michael J , McNally, Elizabeth M , Semsarian, Christopher , Schnabel, Renate B , Benjamin, Emelia J , Kirchhof, Paulus , Roden, Dan M. , Ellinor, Patrick T , Jurgens, Sean J , Christophersen, Ingrid Elisabeth , Olesen, Morten S. , Schnabel, Renate B. , Benjamin, Emelia J. , Rehm, Heidi L. , Kirchhof, Paulus , Bezzina, Connie R. , Ellinor, Patrick T.

Mayo Clinic

European Heart Journal | May 9, 2024 | Volume: 45 | Issue: 34 | Pages: 3111-3123

10.1093/eurheartj/ehae298 | PMID 39028637 Get It

Abstract Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%–11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research—mechanistic, translational, and clinical—is urgently needed.